Several GLP-1 agonists have FDA approval for other indications that may overlap with BED patient populations: Semaglutide (Wegovy) and liraglutide (Saxenda) are approved for chronic weight management in adults with obesity (BMI 30) or overweight (BMI 27) with at least one weight-related comorbidity Semaglutide (Ozempic), liraglutide (Victoza), dulaglutide (Trulicity), and tirzepatide (Mounjaro) are approved for type 2 diabetes management Tirzepatide (Zepbound) is approved for chronic weight management When clinicians prescribe GLP-1 agonists for BED, this constitutes off-label use a legal and common practice in medicine when evidence suggests potential benefit and approved treatments are inadequate
Having a caregiver or partner prefill syringes during a single careful session eliminates the need to perform fine motor tasks every injection day
They were originally developed to help manage type 2 diabetes by regulating blood sugar levels
Many patients complement their weight loss program with treatments like B12 injections for energy support, NAD+ injections for cellular health, or CoolSculpting for targeted body contouring once they've reached or neared their goal weight
Note: Wegovy is now available in both oral (once-daily pill) and injectable (once-weekly) formulations
If I had lost almost no weight, just to have my brain working the way its working, I would stay on this medication forever. On supporting science journalism If you're enjoying this article, consider supporting our award-winning journalism by subscribing
